Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Obeng-Adjei, N, Larremore, DB, Turner, L, Ongoiba, A, Li, S, Doumbo, S, Yazew, TB, Kayentao, K, Miller, LH, Traore, B, Pierce, SK, Buckee, CO, Lavstsen, T, Crompton, PD & Tran, TM 2020, 'Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection', JCI Insight, bind 5, nr. 12. https://doi.org/10.1172/jci.insight.137262

APA

Obeng-Adjei, N., Larremore, D. B., Turner, L., Ongoiba, A., Li, S., Doumbo, S., Yazew, T. B., Kayentao, K., Miller, L. H., Traore, B., Pierce, S. K., Buckee, C. O., Lavstsen, T., Crompton, P. D., & Tran, T. M. (2020). Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection. JCI Insight, 5(12). https://doi.org/10.1172/jci.insight.137262

CBE

Obeng-Adjei N, Larremore DB, Turner L, Ongoiba A, Li S, Doumbo S, Yazew TB, Kayentao K, Miller LH, Traore B, Pierce SK, Buckee CO, Lavstsen T, Crompton PD, Tran TM. 2020. Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection. JCI Insight. 5(12). https://doi.org/10.1172/jci.insight.137262

MLA

Vancouver

Author

Obeng-Adjei, Nyamekye ; Larremore, Daniel B ; Turner, Louise ; Ongoiba, Aissata ; Li, Shanping ; Doumbo, Safiatou ; Yazew, Takele B ; Kayentao, Kassoum ; Miller, Louis H ; Traore, Boubacar ; Pierce, Susan K ; Buckee, Caroline O ; Lavstsen, Thomas ; Crompton, Peter D ; Tran, Tuan M. / Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection. I: JCI Insight. 2020 ; Bind 5, Nr. 12.

Bibtex

@article{4973c832532c4ff596463cc2d2a05fd5,
title = "Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection",
abstract = "BACKGROUNDMalaria pathogenicity is determined, in part, by the adherence of Plasmodium falciparum-infected erythrocytes to the microvasculature mediated via specific interactions between P. falciparum erythrocyte membrane protein (PfEMP1) variant domains and host endothelial receptors. Naturally acquired antibodies against specific PfEMP1 variants can play an important role in clinical protection against malaria.METHODSWe evaluated IgG responses against a repertoire of PfEMP1 CIDR domain variants to determine the rate and order of variant-specific antibody acquisition and their association with protection against febrile malaria in a prospective cohort study conducted in an area of intense, seasonal malaria transmission.RESULTSUsing longitudinal data, we found that IgG antibodies against the pathogenic domain variants CIDRα1.7 and CIDRα1.8 were acquired the earliest. Furthermore, IgG antibodies against CIDRγ3 were associated with reduced prospective risk of febrile malaria and recurrent malaria episodes.CONCLUSIONThis study provides evidence that acquisition of IgG antibodies against PfEMP1 variants is ordered and demonstrates that antibodies against CIDRα1 domains are acquired the earliest in children residing in an area of intense, seasonal malaria transmission. Future studies will need to validate these findings in other transmission settings and determine the functional activity of these naturally acquired CIDR variant-specific antibodies.TRIAL REGISTRATIONClinicalTrials.gov NCT01322581.FUNDINGDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH.",
author = "Nyamekye Obeng-Adjei and Larremore, {Daniel B} and Louise Turner and Aissata Ongoiba and Shanping Li and Safiatou Doumbo and Yazew, {Takele B} and Kassoum Kayentao and Miller, {Louis H} and Boubacar Traore and Pierce, {Susan K} and Buckee, {Caroline O} and Thomas Lavstsen and Crompton, {Peter D} and Tran, {Tuan M}",
year = "2020",
month = jun,
day = "18",
doi = "10.1172/jci.insight.137262",
language = "English",
volume = "5",
journal = "JCI Insight",
issn = "2379-3708",
publisher = "American Society for Clinical Investigation",
number = "12",

}

RIS

TY - JOUR

T1 - Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection

AU - Obeng-Adjei, Nyamekye

AU - Larremore, Daniel B

AU - Turner, Louise

AU - Ongoiba, Aissata

AU - Li, Shanping

AU - Doumbo, Safiatou

AU - Yazew, Takele B

AU - Kayentao, Kassoum

AU - Miller, Louis H

AU - Traore, Boubacar

AU - Pierce, Susan K

AU - Buckee, Caroline O

AU - Lavstsen, Thomas

AU - Crompton, Peter D

AU - Tran, Tuan M

PY - 2020/6/18

Y1 - 2020/6/18

N2 - BACKGROUNDMalaria pathogenicity is determined, in part, by the adherence of Plasmodium falciparum-infected erythrocytes to the microvasculature mediated via specific interactions between P. falciparum erythrocyte membrane protein (PfEMP1) variant domains and host endothelial receptors. Naturally acquired antibodies against specific PfEMP1 variants can play an important role in clinical protection against malaria.METHODSWe evaluated IgG responses against a repertoire of PfEMP1 CIDR domain variants to determine the rate and order of variant-specific antibody acquisition and their association with protection against febrile malaria in a prospective cohort study conducted in an area of intense, seasonal malaria transmission.RESULTSUsing longitudinal data, we found that IgG antibodies against the pathogenic domain variants CIDRα1.7 and CIDRα1.8 were acquired the earliest. Furthermore, IgG antibodies against CIDRγ3 were associated with reduced prospective risk of febrile malaria and recurrent malaria episodes.CONCLUSIONThis study provides evidence that acquisition of IgG antibodies against PfEMP1 variants is ordered and demonstrates that antibodies against CIDRα1 domains are acquired the earliest in children residing in an area of intense, seasonal malaria transmission. Future studies will need to validate these findings in other transmission settings and determine the functional activity of these naturally acquired CIDR variant-specific antibodies.TRIAL REGISTRATIONClinicalTrials.gov NCT01322581.FUNDINGDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH.

AB - BACKGROUNDMalaria pathogenicity is determined, in part, by the adherence of Plasmodium falciparum-infected erythrocytes to the microvasculature mediated via specific interactions between P. falciparum erythrocyte membrane protein (PfEMP1) variant domains and host endothelial receptors. Naturally acquired antibodies against specific PfEMP1 variants can play an important role in clinical protection against malaria.METHODSWe evaluated IgG responses against a repertoire of PfEMP1 CIDR domain variants to determine the rate and order of variant-specific antibody acquisition and their association with protection against febrile malaria in a prospective cohort study conducted in an area of intense, seasonal malaria transmission.RESULTSUsing longitudinal data, we found that IgG antibodies against the pathogenic domain variants CIDRα1.7 and CIDRα1.8 were acquired the earliest. Furthermore, IgG antibodies against CIDRγ3 were associated with reduced prospective risk of febrile malaria and recurrent malaria episodes.CONCLUSIONThis study provides evidence that acquisition of IgG antibodies against PfEMP1 variants is ordered and demonstrates that antibodies against CIDRα1 domains are acquired the earliest in children residing in an area of intense, seasonal malaria transmission. Future studies will need to validate these findings in other transmission settings and determine the functional activity of these naturally acquired CIDR variant-specific antibodies.TRIAL REGISTRATIONClinicalTrials.gov NCT01322581.FUNDINGDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH.

U2 - 10.1172/jci.insight.137262

DO - 10.1172/jci.insight.137262

M3 - Journal article

C2 - 32427581

VL - 5

JO - JCI Insight

JF - JCI Insight

SN - 2379-3708

IS - 12

ER -

ID: 62343236